



## FDA Approved Drugs – February 2016

### Vidhya V

#### Publication History

Received: 12 May 2016

Accepted: 25 May 2016

Published: April-June 2016

#### Citation

Vidhya V. FDA Approved Drugs – February 2016. *Drug Discovery*, 2016, 11(28), 23-24

#### Publication License



This work is licensed under a Creative Commons Attribution 4.0 International License.

#### General Note

Article is recommended to print as digital color version in recycled paper.

### BRIVIACT (BRIVARACETAM)

**Company:** UCB; Approved by February 2016

**Specific Treatments:** partial onset seizures related to epilepsy

#### General Information

Briivact is specifically indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. It is supplied in three formulations: tablet, oral solution and injection for intravenous administration. The recommended starting dosage is 50 mg twice daily (100 mg per day). Based on individual patient tolerability and therapeutic response, the dosage may be adjusted down to 25 mg twice daily (50 mg per day) or up to 100 mg twice daily (200 mg per day).

**Mechanism of Action**

Briivact (brivaracetam) displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the anticonvulsant effect. However, the precise mechanism by which Briivact exerts its anticonvulsant activity is not known.

**Side Effects**

Adverse effects associated with the use of Briivact may include: somnolence/sedation, dizziness, fatigue, nausea/vomiting

drug discovery